DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1500 participants.
Also called NCT05687448
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,500 participants
- Registry
-
NCT05687448
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT05687448. Randomized; no masking; primary purpose treatment. Start 2025-09 (anticipated); primary completion 2025-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
- Acronym
- DIAMOND
- Condition
- Aortic Valve Disease
- Intervention (Drug)
- Apixaban 5 MG Oral Tablet
- Intervention (Drug)
- Aspirin 75 to 100mg once a day
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Record details
- Record id
cardio:ct-nct05687448- Content hash
2b7e11fe6d0c4891ca1d8481f41a17e8503ecee481c12a7303eccfa5c50d63cf